Stem Cell Therapy for Perianal Crohn’s Disease
References
- Aguilera-Castro, L., Ferre-Aracil, C., Garcia-Garcia-de-Paredes, A., Rodriguez-de-Santiago, E., Lopez-Sanroman, A. (2017). Management of complex perianal Crohn’s disease. Ann. Gastroenterol., 230 (1), 33–44.
- Ankrum, J., Ong, J., Karp, J. (2014). Mesenchymal stem cells: Immune evasive, not immune privileged. Nat. Biotech., 32, 252–260.10.1038/nbt.2816432064724561556
- Augello, A., Tasso, R., Negrini, S., Amateis, A., Indiveri, F., Cancedda, R., Pennesi, G. (2005). Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol., 35, 1482–1490.10.1002/eji.20042540515827960
- Bartholomew, A., Sturgeon, C., Siatskas, M., Ferrer, K., Mcintosh, K., Patil, S., Hardy, W., Devine, S., Ucker, D., Deans, R., Moseley, A., Hoffman, R. (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol., 30, 42–48.
- Ciccocioppo, R., Bernardo, M. E., Sgarella, A., Maccario, R., Avanzini, M. A., Ubezio, C., Minelli, A., Alvisi, C., Vanoli, A., Calliada, F., Dionigi, P., Perotti, C., Locatelli, F., Corazzaa, G. R. (2011). Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut, 60 (6), 788–798.10.1136/gut.2010.21484121257987
- Cosnes, J., Cattan, S., Blain, A., Beaugerie, L., Carbonell, F., Parc, R., Gendre, J. P. (2002). Long-term evolution of disease behavior of Crohn’s disease. Inflamm. Bowel Dis., 8, 244–250.10.1097/00054725-200207000-0000212131607
- Dignass, A., Van Assche, G., Lindsay, J. O., Lemann, M., Soderholm, J., Colombel, J. F., Danese, S., D’Hoore, A., Gassull, M., Gomollon, F. et al. (2010). The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: Current management. J. Crohn’s Colitis, 4, 28–62.10.1016/j.crohns.2009.12.00221122489
- Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P., Matteucci, P., Grisanti, S., Gianni, A. M. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99, 3838–3843.10.1182/blood.V99.10.383811986244
- Duijvestein, M., Wildenberg, M. E., Welling, M. M., Hennink, S., Molendijk, I., van Zuylen, V. L., Bosse, T., Vos, A. C. W., de Jonge-Muller, E. S. M., Roelofs, H. et al. (2011). Pretreatment with interferon- γ enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells., 29,1549–1558.10.1002/stem.69821898680
- De la Portilla, F., García-Cabrera, A. M., Rodríguez- Jiménez, R. M., Reyes, M. L., García-Olmo, D. (2016). Autologous and Allogeneic Stem Cell Transplantation for Treatment of Crohn’s Fistulae/New Insights into Inflammatory Bowel Disease. 262 pp. https://www.intechopen.com/books/new-insights-into-inflammatory-bowel-disease/autologous-and-allogeneic-stem-cell-transplantationfor-treatment-of-crohn-s-fistulae (accessed 26 March 2020).
- Friedenstein, A., Chailakhyan, R., Latsinik, N., Panasyuk, A., Keiliss-Borok, I. (1974). Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation, 17, 331–340.10.1097/00007890-197404000-000014150881
- García-Olmo, D., García-Arranz, M., Herreros, D., Pascual, I., Peiro, C., Rodríguez-Montes, J. A. (2005). A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis. Colon Rectum,48 (7), 1416–1423.10.1007/s10350-005-0052-615933795
- Garcia-Olmo, D., Herreros, D., Pascual, I., Pascual, J. A., Del-Valle, E., Zorilla, J., De La-Quintana, P., Garcia-Arranz, M., Pascual, M. (2009). Expanded adipose-derived stem cells for the treatment of complex perianal fistula: A phase ii clinical trial. Dis. Colon Rectum,52 (1),79–86.10.1007/DCR.0b013e318197348719273960
- Gonzalez-Rey, E., Anderson, P., González, M. A., Rico, L., Büscher, D., Delgado, M. (2009). Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut, 58 (7), 929–939.10.1136/gut.2008.168534
- Hellers, G., Bergstrand, O., Ewerth, S., Holmstrom, B. (1980). Occurrence and outcome after primary treatment of anal fistulae in Crohn’s disease. Gut, 21 (6), 525–527.10.1136/gut.21.6.525
- Khalif, I. (2013). Clinical Guidelines for the Diagnosis and Treatment of Adult Patients with Chronic Paraproctitis (fistulas of the anus, fistula of the rectum). Association of Coloproctology Russia, Moscow. 20 pp.
- Knyazev, O. V., Parfenov, A. I., Shcherbakov, P. L., Ruchkina, I. N., Konoplyannikov, A. G. (2013). Cell therapy for refractory Crohn’s disease. Cell Technol. Biol. Med., 3, 145–152.10.1007/s10517-013-2297-8
- Knyazev, O. V., Parfenov, A. I., Shcherbakov, P. L., Konoplyannikov, A. G., Ruchkina, I. N., Lishchinskaya, A. A. (2014). Combined biological therapy of the fistula form of Crohn’s disease. Clinical demonstration. Ther. Arch., 86 (2), 102–105.
- Krampera, M., Glennie, S., Dyson, J., Scott, D., Laylor, R., Simpson, E., Dazzi, F. (2003). Bone marrow mesenchymal stem cells inhibit the response of naïve and memory antigen-specific T cells to their cognate peptide. Blood, 101, 3722–3729.10.1182/blood-2002-07-2104
- Le Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E., Ringden, O. (2003). HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol., 31, 890–896.10.1016/S0301-472X(03)00110-3
- Lei Yea, Xiaowei Wua, Na Yua, Jingxin Panb, Lianming Liaoc, Fangyu (2016). Clinical efficacy and safety of stem cells in refractory Crohn’s disease: A systematic review. Wang J. Cell. Immunother., 2 (1), 21–27.10.1016/j.jocit.2016.01.001
- Lichtenstein, G. R., Van, S., Bala, M., Blank, M., Sands, B. E. (2005). Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology, 128, 862–869.10.1053/j.gastro.2005.01.04815825070
- Munkholm, P., Langholz, E., Davidsen, M., Binder, V. (1995). Disease activity courses in a regional cohort of Crohn’s. Scand. J. Gastroenterol., 30, 699–706.10.3109/003655295090963167481535
- Panes, J. (2016). Stem cell therapy for perianal fistulas in Crohn’s disease. Gastroenterol. Hepatol., 12 (10), 637–640.
- Rutgeerts, P., Feagan, B. C., Lichtenstein, G. R., Mayer, LK. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., Hanauer, S. B. (2004). Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology, 126, 402–413.10.1053/j.gastro.2003.11.01414762776
- Sachar, D. B., Andrew, H. A., Farmer, R. G., Pallone, F. (1992). Proposed classification of patient subgroups in Crohn’s disease. Gastroenterol. Intern., 5, 141–154.
- Sandborn, W. J., Fazio, V. W., Feagan, B. C., Hanauer, S. B. (2003). AGA technical review on perianal Crohn’s disease. Gastroenterology, 125, 1508–1530.10.1016/j.gastro.2003.08.02514598268
- Schnitzler, E., Fielder, H., Ferrante, M., Noman, M., Arijs, I., Assche, G. V., Hoffman, I., Van Steen, K., Vermeire, S., Rutgeerts, P. (2009). Mucosal healing predicts long-term outcome for maintenance therapy with infliximab in Crohn’s disease. Inflamm. Bowel Dis., 15, 1295–1301.10.1002/ibd.2092719340881
- Schwartz, D. A., Loftus, E. V., Jr., Tremaine, W. J., Panaccione, R., Harmsen, W. S., Zinsmeister, A. R., Sandborn, W. J. (2002). The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology, 122 (4), 875–880.10.1053/gast.2002.3236211910338
- Sensebe, L., Krampera, M., Schrezenmeier, H., Bourin, P., Giordano, R. (2010). Mesenchymal stem cells for clinical application. Vox Sang, 98, 93–107.10.1111/j.1423-0410.2009.01227.x19663934
- Solberg, I. C., Yarn, M. H., Hoie, O., Stray, N., Sauar, J., Jahsen, J., Moum, B., Lygren, I. (2007). Clinical course in Crohn’s disease: Results of a Norwegian population-based ten-year follow-up study. Clin. Gastroenterol. Hepatol., 5, 1430–1438.10.1016/j.cgh.2007.09.00218054751
- Solberg, I. C., Lygren, I., Jahnsen, J., Vatn, M. H. (2008). Mucosal healing after initial treatment may be a prognostic marker for long-term outcome in inflammatory bowel disease. Gut, 57, A15.
- Stappenbeck, T., Miyoshi, H. (2009). The role of stromal stem cells in tissue regeneration and wound repair. Science, 324, 1666–1669.10.1126/science.117268719556498
- Tang, L. Y., Rawsthorne, P., Bernstein, C. N. (2006). Are perineal and luminal fistulas associated in Crohn’s disease? A population-based study. Clin. Gastroenterol. Hepatol., 4 (9), 1130–1134.10.1016/j.cgh.2006.06.02116905369
- Tsyb, A. F., Konoplyannikov, A. G., Kolesnikov, A. I., Pavlov, V. V. (2004). The preparation and use in medicine, cell cultures of mesenchymal stem cells of bone marrow. Bull. Russ. Acad. Med. Sci., 59 (9), 71–76.
- Williamson, P. R., Hollinger, M. D., Larch, S. W., Ferrara, A. (1995). Twenty-year review of the surgical management of perianal Crohn’s disease. Dis. Colon. Rectum, 38, 389–392.10.1007/BF020542277720446
- Zuk, P., Zhu, M., Ashjian, P., De Ugarte, D., Huang, J., Mizuno, H., Alfonso, Z. C., Fraser, J. K., Benhaim, P., Hedrick, M. H. (2002). Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell, 13, 4279–4295.10.1091/mbc.e02-02-010513863312475952
Language: English
Page range: 68 - 74
Submitted on: Feb 5, 2020
Accepted on: Mar 17, 2020
Published on: May 11, 2020
Published by: Latvian Academy of Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 6 issues per year
Keywords:
Related subjects:
© 2020 Oleg Knyazev, Anna Kagramanova, Albina Lischinskaya, Irina Korneeva, Mariya Zvyaglova, Anait Babayan, Anatoliy Konoplyannikov, Asfold Parfenov, published by Latvian Academy of Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.